A Randomized, Double-Blind, Placebo-Controlled, Phase 4 Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Donanemab in Adults With Down Syndrome

The goal of this clinical trial is to learn if donanemab can reduce levels of amyloid in the brain, and if donanemab is safe and well-tolerated in participants with Down syndrome.
The main questions it aims to answer are: Does donanemab reduce amyloid in the brain? Is donanemab safe and well-tolerated in people with Down syndrome? Researchers will compare donanemab to a placebo (a look-alike substance that contains no drug) to see if donanemab works to reduce levels of amyloid in the brain.
Participants in the study will be 35-50 years old and will be in the study for 12 months. Participants will then stay in the study for an additional 12 months in an long-term extension where all participants will receive donanemab. Participants who had a reduction in amyloid (measured by amyloid brain scan) by the end of the first 12 months will receive placebo for the long-term extension, while participants who did not have an amyloid reduction will receive study donanemab for the long-term extension. Everyone (participants and study staff) will remain blinded to treatment for the duration of the study.
Participants will:
* Have intravenous (IV) infusions of donanemab (or placebo) every 4 weeks
* Visit the clinic once every other month for checkups and tests. These tests will include brain scans (magnetic resonance imaging [MRI] and positron emission tomography [PET] ), blood draws and memory tests.
* Have a study partner who who can provide information about the participant and can join participant for some of the study visits.

开始日期2026-08-01

申办/合作机构

University of Southern California

[+3]

JPRN-jRCTs051260074

/ RecruitingN/A

Development of an Optimization Model for Determining the Optimal Timing to Discontinue Donanemab Treatment Based on Amyloid PET Image Evaluation

开始日期2026-06-10

申办/合作机构-

NCT07602582

/ Recruiting临床3期

An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM

The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

开始日期2026-05-22

申办/合作机构

Eli Lilly & Co.

100 项与多奈单抗相关的临床结果

登录后查看更多信息

100 项与多奈单抗相关的转化医学

登录后查看更多信息

100 项与多奈单抗相关的专利（医药）

登录后查看更多信息

361

项与多奈单抗相关的文献（医药）

2026-10-01·JPAD-Journal of Prevention of Alzheimers Disease

Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses

Article

作者: Epelbaum, Stéphane ; Khanna, Rashna ; Zimmer, Jennifer A ; Sapin, Christophe ; Jessen, Frank ; Dell'Agnello, Grazia ; Brooks, Dawn A ; Dichter, Sascha ; Hauck, Paula M ; Agosta, Federica ; Doty, Erin ; Evans, Cynthia D ; Sims, John R

BACKGROUND:

In the European Union (EU), donanemab is indicated in adults with early symptomatic Alzheimer's disease who are apolipoprotein E ε4 non-carriers or heterozygotes. Among these, patients without superficial siderosis at baseline, uncontrolled hypertension, or anticoagulant use are eligible.

OBJECTIVE:

To assess efficacy and safety of donanemab in the EU-eligible population.

METHODS:

A post-hoc conservative hybrid imputation method was implemented for clinical efficacy analyses during the TRAILBLAZER-ALZ 2 placebo-controlled period. In the 78-week long-term extension (LTE) participants in the early-start (randomised to donanemab) and delayed-start (randomised to placebo with donanemab initiation during the LTE) groups were compared to a propensity-weighted external control. Participants were switched to placebo after meeting amyloid-based treatment course completion criteria.

RESULTS:

By 76 weeks, donanemab-treated participants in the EU-eligible population had a mean Clinical Dementia Rating Scale (CDR)-Sum of Boxes change from baseline difference from placebo of -0.7 points (95% confidence interval, -1.0, -0.4) and a 40.3% lower risk of disease progression to the next stage (per CDR-Global score). Treatment benefit increased over 154 weeks for non-carriers and heterozygotes, including those meeting treatment course completion criteria by 52 or 76 weeks. In the placebo-controlled period, 119 (19.5%) and 49 (8.0%) donanemab-treated eligible participants experienced amyloid-related imaging abnormalities-edema/effusion and infusion-related reactions, respectively. Safety findings were similar among donanemab-treated participants in the placebo-controlled period and LTE delayed-start group.

CONCLUSIONS:

Consistent with previous TRAILBLAZER-ALZ 2 and LTE findings, donanemab significantly slowed disease progression compared to controls with a manageable safety profile in non-carriers and heterozygotes.

2026-09-01·JOURNAL OF THE NEUROLOGICAL SCIENCES

A case of punctate DWI hyperintense lesions concurrent with ARIA-E during donanemab therapy

Letter

作者: Tanaka, Tomotaka ; Sugie, Kazuma ; Ohara, Hiroya

2026-07-01·AGEING RESEARCH REVIEWS

Serious side effects of Alzheimer’s immunotherapy demand scrutiny

Review

作者: Sensi, Stefano L ; Andalib, Sasan ; Høilund-Carlsen, Poul F ; Alavi, Abass ; Vissel, Bryce ; Costa, Tommaso ; Espay, Alberto J ; Robakis, Nikolaos K ; Neve, Rachael L ; Revheim, Mona-Elisabeth ; Barrio, Jorge R ; Perry, George ; Castellani, Rudolph J ; de Girolamo, Giovanni

Monoclonal antibodies targeting amyloid-β, i.e., lecanemab and donanemab, have recently been approved for treating early Alzheimer's disease (AD). Though these antibodies are by many considered milestones in AD therapy, clinical approvals have been inconsistent due to ongoing debates over their clinical benefit and safety. The reported cognitive decline slowing is modest and often below the thresholds for clinically significant differences on outcome scales. Moreover, these therapies are linked to adverse effects, including infusion reactions, headaches, and nausea, as well as more serious issues like amyloid-related imaging abnormalities (ARIAs), the long-term impact of which remains unclear. In this Viewpoint article, we highlight three safety concerns: ARIAs, accelerated brain volume loss, and therapy-related deaths. ARIAs occur much more frequently in treated AD patients than in placebo groups, yet their functional consequences remain poorly understood. Evidence also suggests that treatment with anti-amyloid antibodies may lead to more brain tissue loss than placebo treatments, though this has received limited attention in trials and regulatory evaluations. Finally, reliable data on therapy-related mortality is scarce due to insufficient access to detailed clinical and neuropathological information. These issues underscore significant uncertainties in assessing the risk-benefit profile of anti-amyloid therapies. A more systematic investigation-including routine brain volume monitoring, functional PET imaging, and independent death evaluations-is crucial for a comprehensive understanding of both benefits and risks in regulatory and clinical decisions.

2,023

项与多奈单抗相关的新闻（医药）

12 小时之前

·研发客

营收猛增73%！MNC中国区业绩黑马现身，多家上调全年预期 | 财报

// • 礼来上半年在中国的营收涨势最猛，同比上涨73%； • 依靠GLP-1产品，礼来和诺和诺德在今年上半年保持了两位数营收增速； • 诺和诺德市值相比巅峰，已缩水2/3。全球制药巨头2026上半年的表现已全部交卷。研发客今年6月曾整理出MNC市值排行前十（详见中国前十VS全球前十，差距有多远？），时隔仅两个月，市值排位又发生新变化：安进和吉利德跃升进入前十榜单。截至8月13日数据，安进市值2245亿美元，吉利德为1716亿美元，分别位列第八、第十位。前三的位置并无悬念。礼来以1.11万亿美元市值持续登顶，强生、艾伯维分别以6274 亿美元、4408亿美元位列第二、第三；并且，据研发客观察，过去两个月，这三家市值水平进一步提升。默沙东、诺华、罗氏、阿斯利康的位次基本不变。诺和诺德市值2030亿美元，徘徊在第九位，相较于其2024年6500亿美元巅峰市值，已缩水2/3。（见下表）而令人唏嘘的是，辉瑞、赛诺菲、BMS这几家老牌跨国药企，自告别前十席位以来，迄今未回归。谁是中国区的赢家今年上半年，多家跨国药企在中国市场的表现不尽如人意。从绝对金额来看，阿斯利康上半年在中国市场的营收达35.1亿美元，位列跨国药企中国区业绩第一，占阿斯利康全球市场的11%。但是，相较去年同期下滑了5%，主要原因为达格列净集采丢标令其失去公立医院市场。默沙东上半年中国区业绩下滑最剧烈，仅收获7.21亿美元，同比下降33%。罗氏同样经历中国区业绩缩水，尽管没有披露具体金额，上半年罗氏中国区销售额‌同比下降 9%‌。礼来上半年在中国的涨势最猛，收入16.35亿美元，同比上涨73%。尽管如此，中国区收入仍然仅占其全球业务的3.8%。2025全年，礼来在中国区营收为19.51亿美元，随着替尔泊肽纳入医保，中国将逐渐成为礼来的新阵地。与礼来争夺同一阵地的诺和诺德，上半年在中国区收入15.25亿美元，基本与去年同期持平。诺华上半年在中国市场的收入约25亿美元，同比增长7%。应对专利悬崖挑战但是，诺华在全球的表现并不如意，上半年整体营收275.21亿美元，同比下降2%。重磅心衰药物Entresto2026上半年24.86亿美元，同比下降46%。此外，Promacta、Lucentis、Promacta、Xolair都出现了较大幅度的业绩下滑。不过，CDK4/6抑制剂Kisqali、核药Pluvicto以及多发性硬化症药物Kesimpta，正在成为新的增长动力。艾伯维也在寻找新的增长点。过去几年对于修美乐专利到期挑战的讨论甚嚣尘上，不过，新的接棒者已经出现，并帮助艾伯维在今年上半年保持两位数营收增速：营收319.92亿美元，同比增长11.2%。为此，艾伯维上调了全年营收预期至674亿~678亿美元，较2025年611.6亿美元的营收同比增长10.8%左右；而去年营收的增速是8.51%。可见，艾伯维对自身业务的信心正在逐渐提升。上半年，艾伯维在免疫学板块获得160.76亿美元收入，同比增长15.7%，占总收入的半壁江山。其中，Skyrizi带来99.88 亿美元收入，同比增长27.3%，Rinvoq收入46.44 亿美元，同比增长24.0%。神经科学业务的潜力同样不可小觑，贡献了61.03亿美元，同比增长22.9%。 GLP-1的高光尽管在市值表现上有所败退，但辉瑞在上半年营收294.84亿美元，排在跨国药企营收榜的第七位，同比增长4%。罗氏299.184亿美元，同比增长6%，强生在制药板块的营收318.1亿美元，同比增长9.4%。毫不夸张的说，这是一个属于GLP-1的时代，礼来依然是最大赢家。依靠替尔泊肽在全球市场的大放异彩，上半年收入427.73亿美元，同比增长49%，这一增速确实令人难以望其项背。基于此，礼来上调了全年的营收预期至850亿~870亿美元。2025年，礼来全年营收651.79亿美元，同比增长44%。如果2026年预期目标能够实现，意味着礼来2026年的营收增速将在33%左右。由此来看，相较于2024~2025年，礼来对全年增速的预期并没有过于激进，甚至有所保留。诺和诺德同样保持两位数增速，上半年营收273.84，同比增长18%。司美格鲁肽全系列贡献 173.12亿美元，其中 Ozempic 91.35亿美元、Wegovy 58.20亿美元、口服 Wegovy 8.45亿美元。降糖口服版Rybelsus上半年销售额15.12亿美元，同比下降19%。值得留意的是，今年一季度业绩公布之后，诺和诺德将2026全年调整后销售额预期，从“同比下降5%~13%”上调至“同比下降4%~12%‌”。二季度财报之后，进一步将全年调整后销售额预期，上调为“同比下降0%~6%”‌，同时，将调整后营业利润预期调整为“同比下降6%至增长0%”。‌‌ 但对于诺和诺德来说，更重要的是如何摆脱对单一产品的过度依赖。相比之下，礼来替尔泊肽的业绩是司美格鲁肽的三倍，且除了替尔泊肽，礼来的BTK抑制剂Japirca、IL-13单抗 Ebglyss、阿尔茨海默症药物Kisunla仍能撑起第二支柱。今年6月，Ebglyss 获FDA批准用于中重度特应性皮炎患者的每8周一次维持给药。吉利德转型成功？吉利德2026年上半年总营收‌147.63 亿美元‌，同比增长7%。HIV板块仍然是最大的增长动力，上半年收入约107.2亿美元，同比增长约11%，占总营收70%以上。 HIV板块中，核心产品Biktarvy在 2026 年上半年实现了‌71.33 亿美元‌的销售额，同比增长6.8%‌。暴露前预防用药（PrEP）在今年二季度销售首次突破10亿美元；其中，Descovy用于PrEP的Q2销售约8亿美元，同比增长60%，长效针剂Yeztugo的Q2销售2.3亿美元，成为长效PrEP新患者首选。基于此，公司将全年HIV销售增速指引由8%上调至9%~10%。不过，Biktarvy纳入美国IRA谈判，价格降幅将在今年底公布。最近几年，吉利德努力通过频繁收购和管线推进，转型成为抗病毒、肿瘤、自免赛道的综合型生物制药企业，以摆脱HIV单一业务依赖。今年二季度，抗肿瘤产品销售8.73亿美元，同比增长3.0%，其中，戈沙妥珠单抗（Trodelvy）卖出4.57亿美元，同比增长26.0%。今年6月，Trodelvy获FDA批准，用于‌不可切除的局部晚期或转移性三阴性乳腺癌‌，意味着该药从后线治疗拓展至一线治疗方案。获批场景包括：不适合免疫治疗的患者‌可单独使用 Trodelvy 作为单药疗法；对于肿瘤‌PD-L1 表达阳性的患者，使用 Trodelvy 联合‌Keytruda治疗。此外，吉利德的CAR-T细胞疗法今年二季度销售4.17亿美元，同比下降14.0%。今年上半年，吉利德完成了对Arcellx、Tubulis、Ouro Medicines的三笔收购，花费将近130亿美元。收购带来的兑现风险仍然存在不确定性。编辑 | 姚嘉 yao.jia@PharmaDJ.com 总第3085期访问研发客网站www.PharmaDJ.com 深度报道和每日新闻抢鲜看

财报专利到期

2026-08-17

·Pharmaceutical Technology

Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval

With FDA approval for TAUKLARIFY in hand, Lantheus intends to continue supporting Alzheimer’s disease therapeutic programs through its Pharma Solutions business while assessing the appropriate path towards broader commercial availability for the PET radiodiagnostic. Credit: Tada Images/Shutterstock.com Lantheus Holdings’ radiodiagnostic agent for identifying tau pathology in adult patients under evaluation for Alzheimer’s disease has secured US Food and Drug Administration (FDA) approval. The Massachusetts-based radiopharmaceutical specialist’s Tauklarify is indicated for positron emission tomography (PET) imaging of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify tau neurofibrillary tangle (NFT) pathology. Alongside amyloid-beta plaque buildups, tau NFTs are a common biomarker used to determine whether an individual has Alzheimer’s. Tau NFTs are abnormal clumps of tau that build up inside brain cells. Tauklarify’s FDA approval was supported by two blinded read studies that analysed Tauklarify PET images from over 500 subjects and included individuals with mild cognitive impairment, mild Alzheimer’s disease dementia, and cognitively unimpaired individuals. All subjects across both studies received an approximate intravenous dose of 185 MBq (5 mCi) of Tauklarify, with scans analysed by independent readers who underwent training on image interpretation and were blinded to subjects’ clinical information and amyloid beta PET results. Scans were classified as positive or negative for tau NFT pathology and compared against a pre-established reference standard based on cognitive status and amyloid beta PET findings. The study demonstrated a high level of accuracy along with strong inter-reader agreement. With FDA approval in hand, Lantheus intends to continue supporting Alzheimer’s disease therapeutic programmes through its pharma solutions business while assessing the most appropriate path towards broader commercial availability of its radiodiagnostic. The company added that its rollout approach will remain aligned with the needs of its partners and be informed by ongoing developments across the Alzheimer’s disease treatment landscape. Lantheus’s CEO, Mary Anne Heino, highlighted that Tauklarify’s FDA clearance reflects the rising importance of tau imaging in Alzheimer’s disease assessment and the developmental programme that led to its radiodiagnostic’s clearance. Heino continued: “As the field continues to advance, clinicians are seeking a more complete understanding of this disease, with tau PET imaging providing information that complements amyloid PET and other diagnostic tools. We remain committed to advancing research that will further define the role of tau imaging in understanding Alzheimer’s disease.” Recent developments in the Alzheimer’s space FDA approval for Lantheus’s radiodiagnostic represents a slight divergence to recent work being done in the Alzheimer’s space, with many diagnostics for pTau evaluation in patients with cognitive impairment taking the form of blood-based tests. Chief among these are Roche’s Elecsys tests. The company’s Elecsys pTau181, a blood-based biomarker test for the preliminary evaluation of Alzheimer’s disease, secured FDA approval in October 2025 , while its pTau217 blood test for pTau measurement obtained a European CE mark in May 2026. The broader development in the Alzheimer’s disease space, meanwhile, has been the FDA’s approval of the first disease-modifying therapies (DMT) for the disease in the form of Biogen & Eisai’s Leqembi and Eli Lilly’s Kisunla in 2023 and 2024, respectively. Despite reimbursement challenges, the drugs are both expected to become blockbuster therapies in 2027 and 2028, respectively, as per GlobalData’s Pharmaceutical Intelligence Centre. GlobalData is the parent company of Pharmaceutical Technology. These may soon be joined by Roche’s trontinemab, for which Roche debuted new efficacy and biomarker data from a portion of its open-label extension (OLE) segment of the Phase Ib/IIa Brainshuttle AD study (NCT04639050) at the 2026 Alzheimer’s Association International Conference (AAIC) in London last month.

临床研究上市批准

2026-08-15

·升机盎然

一文了解礼来（Eli Lilly，LLY）

礼来作为全球百年创新药企，凭借 GLP-1 双靶点药物替尔泊肽稳居全球万亿市值头部药企梯队，与诺和诺德成为仅有的两家市值破万亿药企。公司同步布局肿瘤、自身免疫、阿尔茨海默四大黄金赛道，搭建 “当下现金牛产品 + 中长期管线接力” 的完整成长曲线。本文从发展沿革、核心管线、最新财务、估值拆解、护城河、竞争格局、核心风险七大维度完整复盘。一、百年发展脉络：从胰岛素工业化到 GLP-1 代谢平台龙头1. 奠基期（1876-1982）：胰岛素奠定行业根基 1876 年礼来上校在美国印第安纳波利斯创立企业，率先实现制药标准化生产；1923 年联合多伦多大学完成胰岛素工业化量产，解决全球糖尿病无有效治疗药物的困境，构筑百年基本盘；1982 年推出全球首款重组人胰岛素 Humulin，淘汰动物胰腺提取胰岛素，确立代谢疾病领域长期先发优势。2. 多元化扩张期（1990-2021）：四大治疗板块成型自研推出 SSRI 类抗抑郁药物百优解，开辟精神疾病全新治疗赛道；陆续落地培美曲塞（非小细胞肺癌化疗）、周制剂 GLP‑1 度拉糖肽、JAK 抑制剂巴瑞替尼等重磅品种，完成代谢、肿瘤、自身免疫、神经科学四大核心赛道布局；2022 年替尔泊肽获 FDA 批准，正式开启 GLP‑1 双靶点竞争时代。3. 高速增长期（2022 至今）：GLP‑1 重构企业价值体系替尔泊肽分糖尿病、肥胖两大核心适应症全球持续放量；同步推进口服 GLP‑1、三靶点 Retatrutide 临床研发突破；累计投入超 115 亿美元在美国新建原料药生产基地，同步联合英伟达搭建 AI 药物研发超算平台，由传统化学制药企业转型为覆盖代谢全疾病谱的平台型创新药企。二、四大核心管线：成熟现金产品 + 下一代储备梯队完整布局（一）心脏代谢（核心增长引擎，营收占比 65%）1. 已上市成熟现金产品替尔泊肽（Tirzepatide，商品名穆峰达 ®，GLP‑1/GIP 双受体激动剂）度拉糖肽（度易达 ®）：一周一次长效 GLP‑1，基层 2 型糖尿病基础刚需用药。 Orforglipron（Foundayo®）：口服小分子 GLP‑1，2026Q2 上市首季度销售额 9800 万美元，差异化覆盖排斥注射剂型的患者群体，作为注射类 GLP‑1 重要补充。2. 远期核心管线：Retatrutide 三靶点（GLP‑1/GIP/GCG） 2026 年 7 月全部三期临床完整数据公布，最高剂量组 80 周平均减重 22.6%，覆盖单纯肥胖、糖尿病合并肥胖、心血管并发症肥胖多类人群；计划 2027 年向 FDA 提交上市申请，减重临床数据接近减重手术效果，是未来 3-5 年第二增长曲线核心资产。（二）肿瘤管线：差异化创新，填补耐药临床空白阿贝西利（唯择 ®）：CDK4/6 抑制剂，用于 HR+/HER2‑乳腺癌一线治疗；匹妥布替尼（捷帕力 ®）：全球首款非共价 BTK 抑制剂，适配一代 BTK 抑制剂耐药的 B 细胞血液肿瘤，拥有独家差异化赛道；储备管线：持续通过并购布局核药、新一代 ADC 药物，丰富肿瘤治疗矩阵。（三）自身免疫与炎症巴瑞替尼（艾乐明 ®）：全球首款用于斑秃的口服全身治疗药物，同时覆盖类风湿关节炎、中重度特应性皮炎；依奇珠单抗（拓咨 ®）：IL‑17A 单抗，用于银屑病；Lebrikizumab（IL‑13 单抗）针对难治性特应性皮炎。（四）神经科学（长期战略布局赛道）多奈单抗（记能达 ®Donanemab）：靶向 β 淀粉样蛋白阿尔茨海默病抗体，公司累计投入超 80 亿美元深耕阿尔茨海默管线，适用于早期阿尔茨海默患者；同步推进新一代清除效率更高的 Remternetug，打造远期潜在百亿级赛道。三、2026 最新财务深度拆解（截至 Q2 财报，8 月 5 日官方披露）1. 季度核心经营数据单季总营收：229.7 亿美元，同比 + 48%，显著高于市场一致预期 205.9 亿美元； GAAP 净利润 70.95 亿美元，GAAP EPS7.94 美元（本季度大额并购产生 28 亿美元一次性费用，对 GAAP 利润形成短期拖累）； Non‑GAAP 调整后 EPS 8.38 美元，同比 + 33%，盈利质量超市场预期； Non‑GAAP 综合毛利率 86.3%，高毛利 GLP‑1 产品营收占比持续提升，规模效应不断释放；区域拆分：美国本土营收 144 亿美元，同比 + 33%，减重药物处方量持续扩张；海外市场整体高增，中国医保准入拉动国内业务高速增长。2. 2026 全年上调业绩指引全年总营收区间：850–870 亿美元（此前指引 820–850 亿，区间上限上调 30 亿美元）；全年 Non‑GAAP EPS：35.50–36.50 美元；全年性能利润率上调至 49%–50.5%，经营杠杆持续优化。四、当前估值全景分析（2026.08.04 收盘，LLY 股价 1115.68 美元）1. 核心估值指标表估值指标当前数值行业对比参考解读总市值约 1.05 万亿美元全球头部创新药企梯队仅礼来、诺和诺德万亿市值级别 TTM 滚动 PE 41.6x 传统成熟大药企 15–22x 估值包含 GLP‑1 赛道长期高增长溢价 2026 前瞻 Forward PE 30.7–31.4x 诺和诺德 27–29x 市场已提前定价 Retatrutide 远期增量预期 TTM 市销率 PS 14.5x 传统药企中枢 3–6x 高毛利率、高营收增速支撑估值溢价股息率 0.58% 医药龙头平均 1.5% 现金流优先倾斜研发、产能扩建，分红比例偏低2. 机构一致预期覆盖公司的 31 家卖方机构平均目标价 1283 美元，对应潜在上行空间约 15%；机构目标价区间 850–1600 美元，分歧度较高。分歧核心变量：GLP‑1 行业价格战幅度、Retatrutide 临床落地节奏、美国 IRA 药品强制议价带来的利润冲击。3. 三种估值情景测算（仅逻辑推演，不构成业绩预测）乐观情景：Retatrutide 如期 2027 年获批并快速放量，全球 GLP‑1 药物渗透率持续提升，2027 年公司全年营收突破 1000 亿美元，市场维持 28–30 倍前瞻 PE，市值保持上行；中性情景：替尔泊肽维持稳健增长，赛道竞争逐步加剧，估值中枢回落至 22–25 倍创新药企合理区间；悲观情景：全球医保控费、行业价格战、核心管线临床数据不及预期，估值向传统成熟药企 15–20 倍 PE 区间回归。4. 对标诺和诺德核心差异对比维度礼来 LLY 诺和诺德 NVO 核心产品替尔泊肽双靶点，临床减重数据具备差异化优势司美格鲁肽单靶点，商业化渠道铺设成熟管线布局代谢 + 肿瘤 + 自免 + 阿尔茨海默，多赛道均衡布局，多第二增长曲线储备深耕代谢单一赛道，管线集中于糖尿病、减重领域估值溢价 2026 前瞻 PE 30–31x 2026 前瞻 PE 27–29x 核心风险营收高度依赖替尔泊肽，阿尔茨海默管线临床存在不确定性业务完全绑定 GLP‑1 赛道，无其他成熟重磅板块对冲周期风险五、核心护城河（长期竞争壁垒）完整 GLP‑1 专利矩阵壁垒：覆盖双靶点、三靶点、口服小分子全分子路径专利布局，竞品短期难以绕开核心专利体系；全球超前产能壁垒：百亿级资金提前布局原料药生产基地，锁定未来 5 年全球减重药物供给产能，解决行业普遍产能瓶颈；AI 驱动研发优势：与英伟达共建医药专属超算平台，自研 TuneLab AI 药物研发体系，靶点筛选、临床模拟效率领先同行，叠加持续并购补齐管线短板；多适应症协同壁垒：同一 GLP‑1 分子获批糖尿病、肥胖、睡眠呼吸暂停等多重适应症，单产品最大化市场空间；全球化商业化落地能力：1918 年进入中国市场，苏州自有生产基地可生产替尔泊肽供应国内并出口海外，本土化临床、医保准入推进速度行业领先。六、核心风险点（长期估值压制核心因素）营收结构单一风险：替尔泊肽单产品贡献公司 64.7% 总营收，若出现药物安全舆情、专利纠纷、医保大幅降价，业绩与估值将同步剧烈波动；GLP‑1 赛道竞争持续内卷：全球数十家药企布局同类靶点，国内本土企业注射 / 口服 GLP‑1 陆续上市，中长期行业价格战难以避免，持续压缩产品毛利率；行业同业已发起商业竞争相关诉讼，竞争环境持续白热化；全球医保控费政策压力：美国 IRA 法案强制高价药议价、中国医保年度谈判常态化降价，叠加各国减重高价药支付政策收紧，存在报销范围缩窄、药品持续降价风险；管线临床不确定性：阿尔茨海默类抗体药物疗效存在行业争议，Retatrutide 长期大样本安全性数据仍待持续验证，关键管线临床失败将直接打压市场估值；大额并购财务风险：频繁收购生物技术公司带来一次性费用、商誉减值潜在压力，抬升资产负债表不确定性；远期生物类似药冲击：替尔泊肽核心专利到期后，生物仿制药将持续分流存量市场份额。七、中长期核心结论短期（1–2 年）：替尔泊肽维持高速营收增长，口服 GLP‑1 Orforglipron 逐步贡献增量，业绩高增长确定性较强；但当前 30 倍以上前瞻 PE 已充分定价乐观增长预期，股价容错空间极小，业绩小幅不及预期易引发估值回调。中长期（3–5 年）：三靶点 Retatrutide 是公司第二增长核心资产，若顺利商业化落地，可对冲 GLP‑1 赛道价格战冲击；同时肿瘤、自免、阿尔茨海默管线逐步兑现价值，逐步降低单一产品营收依赖。长期（5 年以上）：依托完善的 GLP‑1 专利管线、超前全球产能、AI 赋能研发体系，公司有望持续维持代谢疾病龙头地位；但全球医保控费、赛道同质化竞争将长期压制估值中枢，难以长期维持当前极高估值溢价。权威参考资料一、官方一手数据源 Eli Lilly 2026 Q2 官方财报及业绩发布会纪要（，2026.08.05）礼来医学中国官网：替尔泊肽中国三期 SURMOUNT-CN 完整临床数据、多奈单抗适应症资料（）礼来官方 Retatrutide 三靶点三期临床 TOPLINE 公告（2026.07）礼来全球产能扩建、英伟达 AI 超算合作官方新闻稿（2025–2026）二、机构研报数据源东吴证券：《礼来 2026Q2 业绩点评：GLP-1 持续高景气，全年指引上调》（2026.08.06）界面新闻医线 Insight：《礼来 vs 诺和诺德：GLP-1 巨头竞争格局深度复盘》（2026.07.21） MarketBeat、LSEG 路孚特：31 家卖方机构一致目标价、盈利一致预期数据（2026.08）三、学术临床文献数据源 Indian Journal of Physiology and Pharmacology：Retatrutide 系统性临床疗效综述（2026） JAMA 系列期刊：替尔泊肽全球多地区肥胖三期完整临床论文免责声明一（投资金融风险声明）本文仅为企业基本面科普、行业客观数据整理与原创逻辑分析，不构成任何股票、基金、生物医药相关投资建议、交易策略、买卖操作指引，不承诺任何收益预测。文中全部营收、估值、临床数据、业绩指引均取自公开市场资料，数据存在滞后、后续修正、调整可能性，作者不对数据绝对准确性、完整性承担任何责任。生物医药行业受政策、临床结果、专利、竞品、医保、药品安全舆情多重不可控因素影响，企业业绩、二级市场股价存在大幅波动风险，所有投资决策请读者独立判断、自行承担全部盈亏风险。任何依据本文内容做出的投资亏损，由投资人自身承担！免责声明二（医药医疗科普声明）文中涉及所有药品（替尔泊肽、阿贝西利、多奈单抗等）适应症、疗效、临床数据仅用于产业行业分析，不构成专业医疗诊断、用药指导、个体化诊疗方案建议。糖尿病、肥胖、肿瘤、阿尔茨海默、自身免疫疾病患者，必须前往正规医疗机构，在执业医师指导下完成身体评估、获取处方、规范用药，禁止仅凭本文内容自行购药、调整药量、擅自停药。药品存在个体差异、过敏风险、不良反应风险，不同国家 / 地区药品获批适应症、医保报销政策存在明显差异，不可将产业销售、临床群体数据等同于个人治疗效果参考。本文未推广、未售卖任何处方药、减重相关药物，不引导线下、跨境非正规渠道购药；非法渠道流通药品存在严重健康安全隐患。

100 项与多奈单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11500	多奈单抗	-	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
认知障碍	加拿大	Eli Lilly Canada, Inc.	2026-07-03
阿尔茨海默病引起的痴呆症	英国	Eli Lilly & Co.	2024-10-23
阿尔茨海默病引起的痴呆症	英国	Eli Lilly Nederland BV	2024-10-23
轻度认知障碍	英国	Eli Lilly & Co.	2024-10-23
轻度认知障碍	英国	Eli Lilly Nederland BV	2024-10-23
阿尔茨海默症	美国	Eli Lilly & Co.	2024-07-02

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
精神障碍	申请上市	加拿大	Eli Lilly Canada, Inc.	-
淀粉样蛋白斑	临床3期	美国	Eli Lilly & Co.	2026-05-22
淀粉样蛋白斑	临床3期	日本	Eli Lilly & Co.	2026-05-22
神经认知障碍	临床3期	中国	Eli Lilly & Co.	2022-10-10
神经认知障碍	临床3期	阿根廷	Eli Lilly & Co.	2022-10-10
神经认知障碍	临床3期	澳大利亚	Eli Lilly & Co.	2022-10-10
神经认知障碍	临床3期	波兰	Eli Lilly & Co.	2022-10-10
神经认知障碍	临床3期	韩国	Eli Lilly & Co.	2022-10-10
神经认知障碍	临床3期	西班牙	Eli Lilly & Co.	2022-10-10
神经认知障碍	临床3期	中国台湾	Eli Lilly & Co.	2022-10-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04437511 (TRAILBLAZER-ALZ 2, Pubmed \| Neurol Clin Pract)	临床2期	阿尔茨海默症	251	Donanemab (Mild cognitive impairment or mild Alzheimer's disease)	齋壓襯壓顧窪衊願選鑰(鹹醖壓壓窪積壓遞艱獵) = 鑰壓廠製窪顧觸鑰淵鹽範製餘觸鏇憲艱憲蓋鬱 (鬱淵鹹襯蓋艱鬱鏇醖鑰 ) 更多	积极	2026-06-01
NCT05738486 (TRAILBLAZER-ALZ 6, CTAD2025)	临床3期	阿尔茨海默症	840	Donanemab standard dosing regimen	醖願壓選願鬱繭壓遞壓(齋夢鏇鹽壓鬱積製顧積) = 製蓋艱鬱糧膚積廠壓齋製醖鹽醖獵齋憲衊醖窪 (鬱構選選餘網憲範醖選 ) 更多	积极	2025-12-01
NCT05738486 (TRAILBLAZER-ALZ 6, CTgov)	临床3期	阿尔茨海默症 \| 神经认知障碍	1,175	Placebo+Donanemab (1400 mg Donanemab - Standard Regimen)	獵簾憲範築鏇醖積夢鬱 = 構遞網簾構積窪膚願簾糧網襯選鹹襯鹹製餘範 (網衊願齋壓遞窪鏇簾繭, 鏇願膚壓網鏇選襯願壓 ~ 鏇製選網憲網選遞艱獵) 更多	-	2025-11-14
				Placebo+Donanemab (1400 mg Donanemab - Dose Skipping)	獵簾憲範築鏇醖積夢鬱 = 鹽網鹹遞築繭艱憲遞觸糧網襯選鹹襯鹹製餘範 (網衊願齋壓遞窪鏇簾繭, 積餘願鏇構築範網壓蓋 ~ 網繭膚蓋獵艱衊糧艱廠) 更多
NCT04437511 (TRAILBLAZER-ALZ 2, PRNewswire) 人工标引	临床3期	阿尔茨海默症	-	Kisunla	鹹鏇獵憲餘積遞鏇觸遞(構遞鹹膚築鹹繭獵淵憲): Difference = -0.6 更多	积极	2025-07-30
				Neuroimaging Initiative (untreated external cohort)
NCT05108922 (TRAILBLAZER-ALZ 4, Pubmed \| Alzheimers Dement)	临床3期	阿尔茨海默症 amyloid plaque clearance	148	Donanemab	選齋廠鏇壓壓廠繭膚鹽(網積憲膚鏇範範築簾壓) = 蓋鬱獵繭願築襯醖淵選壓窪夢醖築積鑰構壓鹹 (製齋選積淵鏇鹽淵積鏇 ) 更多	积极	2025-05-01
				Aducanumab	選齋廠鏇壓壓廠繭膚鹽(網積憲膚鏇範範築簾壓) = 齋衊繭鏇願鹹積壓觸襯壓窪夢醖築積鑰構壓鹹 (製齋選積淵鏇鹽淵積鏇 ) 更多
NCT04437511 \| NCT03367403 (TRAILBLAZER-ALZ and ALZ 2, Pubmed \| JAMA Neurol)	N/A	阿尔茨海默症 APOE ε4 allele number \| amyloid levels	3,030	Donanemab	積蓋齋醖蓋鹹壓網構壓(蓋選獵齋齋窪鏇艱築鹹) = 夢鹽襯艱願鏇衊淵齋積蓋鏇鑰觸壓網窪夢獵鏇 (製願鏇齋廠觸醖鏇簾遞 ) 更多	积极	2025-05-01
				Placebo	積蓋齋醖蓋鹹壓網構壓(蓋選獵齋齋窪鏇艱築鹹) = 繭遞壓顧鑰簾遞範顧鏇蓋鏇鑰觸壓網窪夢獵鏇 (製願鏇齋廠觸醖鏇簾遞 ) 更多
NCT05738486 (TRAILBLAZER-ALZ 6, Company_Website 1 \| Company_Website 2) 人工标引	临床3期	阿尔茨海默症	843	received two vials (700 mg) of donanemab for the first three infusions, then four vials (1400 mg) thereafterdonanemab for the first three infusions, then four vials (1400 mg) thereafter (Standard Dosing Regimen)	壓築齋鹽觸願範築範鏇(製艱網遞襯製顧積廠選) = 醖夢鹽窪鹽顧鹽願網顧鹽選築餘廠夢鏇願壓鬱 (廠積範獵夢餘醖餘製積 ) 更多	积极	2024-10-29
				received 1 vial (350 mg) of donanemab for the first infusion, two vials (700 mg) for the second infusion, three vials (1,050 mg) for the third infusion,donanemab for the first infusion, two vials (700 mg) for the second infusion, three vials (1,050 mg) for the third infusion, and four vials (1400 mg) per infusion thereafter (Modified Titration)	壓築齋鹽觸願範築範鏇(製艱網遞襯製顧積廠選) = 遞顧鹹衊鹽齋製蓋簾艱鹽選築餘廠夢鏇願壓鬱 (廠積範獵夢餘醖餘製積 ) 更多
NCT05026866 (TRAILBLAZER-ALZ 3, CTAD2024)	临床3期	阿尔茨海默症 P-tau217	2,196	Donanemab	遞鏇願遞衊積積壓廠壓(襯構衊選衊糧襯選糧築) = 窪鹹壓壓憲鏇夢膚觸鹽顧糧簾網餘簾醖選襯鑰 (遞蓋夢鹽顧襯顧窪製醖, 0 ~ 0.84) 更多	积极	2024-10-29
				Placebo	遞鏇願遞衊積積壓廠壓(襯構衊選衊糧襯選糧築) = 廠糧膚鏇壓構淵夢獵顧顧糧簾網餘簾醖選襯鑰 (遞蓋夢鹽顧襯顧窪製醖, 0 ~ 1.34) 更多
NCT04437511 (TRAILBLAZER-ALZ 2, CTAD2024)	临床3期	阿尔茨海默症 amyloid \| tau	824	Donanemab	膚壓蓋鹽壓選糧範構憲(憲艱鬱餘夢淵鹽廠願壓) = 鹹夢簾築廠壓淵鏇糧壓糧艱淵齋積網餘糧淵鏇 (構憲鬱繭顧積鏇積蓋鹹 ) 更多	积极	2024-10-29
				Placebo	膚壓蓋鹽壓選糧範構憲(憲艱鬱餘夢淵鹽廠願壓) = 築鬱襯範艱網鹹淵膚艱糧艱淵齋積網餘糧淵鏇 (構憲鬱繭顧積鏇積蓋鹹 ) 更多
NCT05533411 (CTgov)	临床1期	-	36	Placebo (Placebo)	齋繭顧糧鹹網觸積顧積 = 範積窪簾鬱簾繭網蓋積鹽範膚築選衊壓襯淵鹹 (夢餘夢選窪壓遞積鑰窪, 壓繭鏇顧積積積鬱製築 ~ 鑰簾廠顧齋網蓋觸遞鹽) 更多	-	2024-10-04
				Donanemab (700 mg Donanemab)	齋繭顧糧鹹網觸積顧積 = 遞蓋糧願獵襯獵顧糧糧鹽範膚築選衊壓襯淵鹹 (夢餘夢選窪壓遞積鑰窪, 窪鹹糧願窪糧顧夢簾鑰 ~ 淵鬱鏇繭鑰鏇顧願膚積) 更多